Clinical Products Advisory

Clinical product evaluation committee terms of reference

  • 1. Aim

    The aim of the Clinical Product Evaluation committee is to ensure the hospital evaluates and selects medical devices that are:

    • Most appropriate for their clinical practice
    • Suitable for use in each clinical area
    • Readily available
    • Cost effective
    • Meet relevant standards

    For further information regarding the evaluation and selection of medical devices for the RCH, refer to the Clinical Products Advisory homepage.

    2. Accountability

    The Clinical Product Evaluation committee reports to the Clinical Leadership Team via the Executive Director, Nursing Services..

    3. Responsibilities

    • To manage the entry of medical devices into the Royal Children's Hospital to ensure safety, efficacy and quality and standards are met.
    • To manage and facilitate both major and minor procurements and subsequent, evaluations to ensure the most appropriate medical device is purchased in the most cost effective manner.
    • To have clear guidelines for introducing new medical devices     
    • To draft policies and guidelines for the introduction of new medical devices.
    • To develop and implement an assessment tool for the evaluation of medical devices
    • Ensure evaluation committees are aware of probity and procurement responsibilities.
    • Identification of risk and the management of the risk

    4. Committee Membership

    Material Resources Manager
    Chief Biomedical Engineer
    Clinical Products Advisor
    Others may be invited to meetings as required

    5. Meeting Times

    The Clinical Product Evaluation committee will meet as required

    6. Chair

    The chairperson will be the Clinical Products Advisor, or in their absence, the Biomedical Engineering Manager.

    7. Minutes

    Minutes are to be recorded for each meeting, are to be distributed to all committee members and are to be tabled at the next scheduled meeting.

    8. Review

    Terms of Reference will be reviewed at least once per annum.